Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial

Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder for which there are currently no disease-modifying therapies. The neuropathology of PSP is associated with the accumulation of hyperphosphorylated tau in the brain. We have previously shown that protein phosphatase 2 a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kelly L Bertram, Lucy Vivash, Dennis Velakoulis, Leonid Churilov, Thomas Kimber, David Darby, Terence J O’Brien, Charles B Malpas, Christopher M Hovens, Simon J G Lewis, Joanne Fielding, Andrew H Evans, Stephen Tisch, John D O’Sullivan, Ian H Harding, Meaghan Clough, Cassandra Marotta, Scott Kolbe, Meng Law
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2021-12-01
Col·lecció:	BMJ Open
Accés en línia:	https://bmjopen.bmj.com/content/11/12/e055019.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!